Lymphoma-Myeloma-

Lymphoma-Myeloma-

Offline Online

Denosumab More Cost Effective v Zoledronic Acid in Multiple Myeloma

356 0 Acute Lymphoblastic Leukemia
Play Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Date added (newest)

Denosumab gives clinicians more choices for treating multiple myeloma

Denosumab gives clinicians more choices for treating multiple myeloma

What are the next steps for Denosumab?

What are the next steps for Denosumab?

Is it possible to switch from one bone targeting agent to another

Is it possible to switch from one bone targeting agent to another

Is it possible to switch from one bone targeting agent to another in Multiple Myeloma?

Is it possible to switch from one bone targeting agent to another in Multiple Myeloma?

Denosumab More Cost Effective v Zoledronic Acid in Multiple Myeloma

Denosumab More Cost Effective v Zoledronic Acid in Multiple Myeloma

Economic Analysis Denosumab v Zoledronic Acid in Multiple Myeloma

Economic Analysis Denosumab v Zoledronic Acid in Multiple Myeloma

Denosumab gives clinicians more choices for treating multiple myeloma

355 0 Acute Lymphoblastic Leukemia

Raje, Noopur MD of the Massachusetts General Hospital Cancer Center highlights that denosumab now gives clinicians more choices for treating multiple myeloma.

Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

What are the next steps for Denosumab?

298 0 Acute Lymphoblastic Leukemia

Raje, Noopur MD of the Massachusetts General Hospital Cancer Center discusses the next steps for Denosumab at the Lymphoma-Myeloma 2017 meeting in New York.

Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Is it possible to switch from one bone targeting agent to another

154 0 Acute Lymphoblastic Leukemia

Raje, Noopur S., MD from Massachusetts General Hospital Cancer Center asks the question is it possible to switch from one bone targeting agent to another in multiple myeloma?

Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Is it possible to switch from one bone targeting agent to another in Multiple Myeloma?

235 0 Acute Lymphoblastic Leukemia

Raje, Noopur, MD of Massachusetts General Hospital Cancer Center discusses if it is possible to switch from one bone targeting agent to another in Multiple Myeloma?

Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Denosumab More Cost Effective v Zoledronic Acid in Multiple Myeloma

356 0 Acute Lymphoblastic Leukemia

Noopur Raje, MD of Massachusetts General Hospital Cancer Center outlines how the recently released economic analysis of Denosumab v. Zoledronic Acid found that Denosumab was overall more cost effective. Dr. Raje presented these findings at the 2017 Lymphoma-Myeloma meeting in New York.

Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Economic Analysis Denosumab v Zoledronic Acid in Multiple Myeloma

270 0 Acute Lymphoblastic Leukemia

Noopur Raje, MD of Massachusetts General Hospital Cancer Center discusses her findings in which Denosumab is favored in newly diagnosed multiple myeloma patients from a recent economic analysis of Denosumab v Zoledronic Acid in Multiple Myeloma at the 2017 Lymphoma and Myeloma meeting in New York.

Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
My videos
Denosumab gives clinicians more choices for treating multiple myeloma

Denosumab gives clinicians more choices for treating multiple myeloma
Raje, Noopur MD of the Massachusetts General Hospital Cancer Center highlights that denosumab now gives clinicians more choices for treating multiple myeloma.
355 Views
6 years Ago
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
What are the next steps for Denosumab?
What are the next steps for Denosumab?
298 Views
Is it possible to switch from one bone targeting agent to another
Is it possible to switch from one bone targeting agent to another
154 Views
Is it possible to switch from one bone targeting agent to another in Multiple Myeloma?
Is it possible to switch from one bone targeting agent to another in Multiple Myeloma?
235 Views
Denosumab More Cost Effective v Zoledronic Acid in Multiple Myeloma
Denosumab More Cost Effective v Zoledronic Acid in Multiple Myeloma
356 Views
Economic Analysis Denosumab v Zoledronic Acid in Multiple Myeloma
Economic Analysis Denosumab v Zoledronic Acid in Multiple Myeloma
270 Views
Loading